AVEO Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31^st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 11:00 a.m. (PT) in San Francisco.
A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at Online Pharmacy. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.
About AVEO
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. AVEO’s proprietary Human Response Platform^TM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.

Research and Markets: Global Human Vaccines Market 2011-2015

Research and Markets has announced the addition of the "Global Human Vaccines Market 2011-2015" report to their offering.
Executive Summary
TechNavio Announces the Publication of its Report - Global Human Vaccines Market 2011-2015
Buy Aldara (Imiquimod) pills online without prescription TechNavio today launched its report Global Human Vaccines Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers and understanding of the present and the future landscape of the market.
Commenting on the report, an analyst from TechNavio's Healthcare team said; 'The Global Human Vaccines market possesses enough growth opportunities for the vendors in the market because of the high demand for different vaccines that can counter diseases such as hepatitis, cancer, and influenza. Since the market is lucrative, vendors are investing heavily in R&D activities to develop innovative vaccines. This has resulted in the introduction of new technologies such as dendritic cell vaccine preparation, DNA vaccine preparation, T-cell receptor peptide vaccine preparation, and recombinant vector vaccine preparation.'
According to the report, the growing need to prevent viral infections has increased the use of vaccines across the globe. This is one of the major factors driving the growth of the market.
Further, the report also discusses that the shortage of vaccines to meet the market demand in the developing countries is adversely affecting the growth of the Global Human Vaccines market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
Key Topics Covered:
1. Executive Summary
2. Introduction
3. Market Coverage
Market Overview
Key Products
4. Market Landscape
5. Geographical Segmentation
6. Key Leading Countries
7. Rate of Incidence and Prevalence
8. Vendor Landscape
9. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 GlaxoSmithKline plc
15.2 Sanofi S.A.
15.3 Pfizer Inc.
15.4 Merck and Co. Inc.
16. Other Reports in this Series

Testosterone Supplements Help Heart Failure Patients Exercise More And Breathe Better

Heart failure patients who take testosterone supplements may find they breathe better and are able to do more exercise, researchers from the University of Alberta in Edmonton, Canada, reported in Circulation Heart Failure. The authors had gathered data on four randomized human studies of patients with moderate-to-severe chronic heart failure. They had been administered testosterone supplements by gel, patch or injection.

The results of the four studies showed that participants who had been given testosterone supplements had a 50% higher score in a six-minute walking test, compared to those on placebo. Buy Moduretic tabs online without prescription

The authors also found that 35% of patients on testosterone supplements had a 1 to 2 grade improvement in their condition, according to the New York Heart Association classification, versus just 9.8% among those not on the supplements.

Testosterone therapy helped patients gain muscle mass and skeletal endurance rapidly; a gain that persisted for at least 12 months.

Author Justin A. Ezekowitz, M.D., M.Sc., said:

"The improvement in exercise capacity was consistent across all of the studies. Compared to patients in placebo groups, the differences were striking."

Larger trials are required, which could confirm these findings, before testosterone supplements could be recommended for heart failure patients, the researchers explained. This therapy targets skeletal muscle rather than cardiac muscle.

84% of the 198 patients in the studies were male. Their average age was 67 years. One of the studies focused entirely on adult females, who were given lower doses of testosterone than males - the participants in this study also experienced similar benefits.

In none of the four studies were any significant adverse events reported, including exercise- or treatment-related cardiovascular events. No increased rates in prostate cancer or prostate-related conditions were reported either.

Ezekowitz said:

"We don't want patients and their loved ones rushing to buy testosterone supplements online, or physicians to misinterpret the findings. First the results need to be corroborated in large clinical trials."